Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Antiretroviral therapy

- PMLiVE

EU announces agreement with Gilead for remdesivir supply

Drug was granted conditional marketing authorisation in the EU in July

- PMLiVE

Gilead agrees $21bn buyout of Immunomedics

Pharma company gains rights to ADC Trodelvy

- PMLiVE

Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19

The combination treatment hit the primary study endpoint of a reduction in recovery time

- PMLiVE

Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops

Disruption to uptake of HIV and hepatitis C drugs caused by pandemic

- PMLiVE

Gilead makes a play for novel cancer drug with Tizona deal

Pharma company continues oncology biotech spending spree

- PMLiVE

Gilead and Arcus complete closing of ten-year immunotherapy partnership

Deal emphasises Gilead's focus on immuno-oncology

- PMLiVE

Gilead reports remdesivir cuts risk of death in severe COVID-19 patients

Also reveals new analyses from compassionate use programme

- PMLiVE

UPDATED: Gilead drops remdesivir’s orphan drug designation

Decision comes amid intense public criticism of the regulatory status

- PMLiVE

Gilead halts individual requests for COVID-19 hopeful remdesivir

Will now focus on expanded access programmes and backlog

- PMLiVE

NHS England will make PrEP for HIV available in April

Will be made available to patients at risk of contracting infection

- PMLiVE

Gilead drug reduces HIV viral reservoir, says researcher

Treatment with drug was associated with longer viral suppression

- PMLiVE

Gilead swoops on Forty Seven with $4.9bn all-cash deal

Takeover is latest in a string of billion-plus deals signed by Gilead

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links